FrancisJ.GilesMD

Oncology • San Antonio, TX

Hematologic Oncology

NMDTI

Join to view full profile

Dr. Giles is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Giles' full profile

Already have an account?

Office
7979 Wurzbach Rd
San Antonio, TX 78229
Phone+1 210-450-1000

Fax+1 210-450-1150

Education & Training

National University of Ireland, GalwayClass of 1982

Certifications & Licensure

CA State Medical License 1997 - 2025
TX State Medical License 1998 - 2025
IL State Medical License 2013 - 2023
Royal College of PathologyHematology

Clinical Trials

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia Start of enrollment: 1999 Jul 01
Completed
Phase 1
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy Start of enrollment: 2000 Mar 01
Completed
Phase 1, Phase 2
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia Start of enrollment: 2000 Dec 11
Completed
Phase 2
Study of ABT-751 in Patients With Refractory Hematologic Malignancies Start of enrollment: 2002 Dec 01
Completed
Phase 1
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma Start of enrollment: 2004 Apr 01
Completed
Phase 1, Phase 2
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia Start of enrollment: 2005 Nov 01
Completed
Phase 2
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase Start of enrollment: 2004 Apr 01
Completed
Phase 2
CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2004 May 01
Terminated
Phase 2
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Start of enrollment: 2004 May 01
Completed
Phase 1
XK469R in Treating Patients With Refractory Hematologic Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 1
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
Terminated
Phase 2
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2007 Jul 24
Terminated
Phase 1, Phase 2
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies Start of enrollment: 2006 May 01
Completed
Phase 1, Phase 2
Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 2008 Oct 01
Completed
Phase 2
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Start of enrollment: 2009 Nov 01
Completed
Phase 1
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Start of enrollment: 2010 Jun 01
Completed
Phase 3
NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Start of enrollment: 2017 May 25
Completed
Early Phase 1
9-ING-41 in Patients With Advanced Cancers Start of enrollment: 2019 Jan 04
Active, not recruiting
Phase 2
Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R Kelly, Vivian G Oehler
Leukemia. 2024-10-01
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran
Clinical Cancer Research. 2024-02-01
2 citations
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BY...
Gianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, Pilar Giraldo-Castellano, Fausto Castagnetti
Leukemia. 2024-01-01

Abstracts/Posters

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia
Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Francis J. Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
Frank Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib
Francis J. Giles, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from t...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

$Moxetumomab Pasudotox in Heavily Pre-Treated Patients with relapsed/refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Trial$
Moxetumomab Pasudotox in Heavily Pre-Treated Patients with relapsed/refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal TrialFebruary 24th, 2021
9-ING-41, a Small Molecule Inhibitor of GSK-3beta, Potentiates the Effects of Anticancer Therapeutics in Bladder CancerDecember 27th, 2019
Estudio Descubre Nueva Manera De Hacer Más Eficaz a La Quimioterapia Contra El Cáncer PancreáticoSeptember 25th, 2019
Join now to see all

FrancisJ.GilesMD

Dr. Giles is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.